AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39531369
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (FF/VI 100/25μg or UMEC/VI 62.5/25μg)
Trial: 39531423
Drug: Pembrolizumab 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 400 mg every 6 weeks
Trial: 39532348
Drug: Individualised transfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised transfusion strategy (prescription of RBCT restricted to patients with Hb ≤9.0 g/dL and oxygen extraction ratio)
Trial: 39532363
Drug: Social robot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social robot as cotherapist during 9 weekly sessions (B)
Trial: 39532363
Drug: Baseline without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline without the robot during 4 weekly sessions (A)
Trial: 39532363
Drug: Follow-up without
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up without the robot during 4 weekly sessions (C)
Trial: 39532835
Drug: Entinostat 5
RxNorm normalized name: entinostat
DrugBank: Entinostat (DB11841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entinostat 5 mg orally once weekly for 14-day lead-in, followed by entinostat and nivolumab (PD1 inhibitor)
Trial: 39532861
Drug: Neutralizing antibody
RxNorm normalized name: Neutralizing antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing antibody titer
Trial: 39532861
Drug: Anti-Spike binding
RxNorm normalized name: spike lavender oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Spike binding antibody concentration
Trial: 39533115
Drug: Vicadrostat (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicadrostat (10 mg)
Trial: 39533204
Drug: PEG-rhG-CSF on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhG-CSF on day 7 after chemotherapy
Trial: 39533204
Drug: PEG-rhG-CSF on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhG-CSF on day 3 after chemotherapy
Trial: 39533437
Drug: Adaptive strategies
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive strategies for timely treatment adoption
Trial: 39534099
Drug: Livmoniplimab monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Livmoniplimab monotherapy (3mg to 1500mg Q2W)
Trial: 39534099
Drug: Livmoniplimab in
RxNorm normalized name: Livmoniplimab
DrugBank: Livmoniplimab (DB18939)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Livmoniplimab in combination with budigalimab (500mg Q4W)
Trial: 39534390
Drug: PEMF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEMF therapy plus eccentric exercise
Trial: 39534593
Drug: Carrageenan- and
RxNorm normalized name: Carrageenan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrageenan- and sorbitol-containing nasal spray (CS)
Trial: 39534972
Drug: Brexpiprazole 2
RxNorm normalized name: brexpiprazole 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole 2 or 3 mg/day
Trial: 39535462
Drug: Tozorakimab 60
RxNorm normalized name: TOZORAKIMAB
DrugBank: MEDI3506 (DB16473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tozorakimab 60 mg
Trial: 39535462
Drug: Tozorakimab 300
RxNorm normalized name: TOZORAKIMAB
DrugBank: MEDI3506 (DB16473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tozorakimab 300 mg
Trial: 39535462
Drug: Tozorakimab 600
RxNorm normalized name: TOZORAKIMAB
DrugBank: MEDI3506 (DB16473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tozorakimab 600 mg
Trial: 39535685
Drug: IXE/IXE (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IXE/IXE (continuous treatment)
Trial: 39535685
Drug: IXE/PBO (interrupted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IXE/PBO (interrupted treatment)
Trial: 39535685
Drug: IXE (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IXE (continuous treatment)
Trial: 39535812
Drug: Symptom screening
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom screening with SSPedi (daily for 5 days)
Trial: 39536019
Drug: Home-based active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based active tDCS (HB-a-tDCS) on the left dorsolateral prefrontal cortex (l-DLPFC)
Trial: 39536238
Drug: Tirzepatide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide (all doses combined)
Trial: 39536246
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antioxidant supplements)
Trial: 39536433
Drug: CDK 4/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK 4/6 inhibitors (CDK 4-6i)
Trial: 39536433
Drug: Capecitabine (second-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (second-line treatment)
Trial: 39536433
Drug: Taxane-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane-based chemotherapy (second-line treatment)
Trial: 39536433
Drug: Everolimus plus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus plus exemestane (second-line treatment)
Trial: 39536433
Drug: Fulvestrant (second-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant (second-line treatment)
Trial: 39536433
Drug: Second-line treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line treatments (overall)
Trial: 39536455
Drug: Ad26/protein preF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26/protein preF RSV vaccine
Trial: 39536477
Drug: 3-antigen HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-antigen HBV vaccine (3-A-HBV)
Trial: 39536477
Drug: 1-antigen HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-antigen HBV vaccine (1-A-HBV)
Trial: 39536780
Drug: HIFES and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIFES and Sync RF+ treatment (single 20-min treatment on the submental area)
Trial: 39536847
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy in patients with nonelevated hsCRP and noncarrier of CYP2C19 LoFA
Trial: 39536847
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone in patients with nonelevated hsCRP and noncarrier of CYP2C19 LoFA
Trial: 39536847
Drug: Dual/single antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual/single antiplatelet therapy in patients with elevated hsCRP
Trial: 39537191
Drug: Standard dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dual antiplatelet therapy (DAPT; aspirin plus ticagrelor/prasugrel)
Trial: 39537385
Drug: Drug-free group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free group (both GC and HCQ withdrawal)
Trial: 39538001
Drug: Avacincaptad pegol
RxNorm normalized name: Avacincaptad pegol
DrugBank: Avacincaptad pegol (DB15165)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avacincaptad pegol (ACP) 2 mg
Trial: 39538139
Drug: Antihypertensive medication
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medication (various classes including thiazide diuretics, ACE inhibitors, ARBs, calcium channel blockers)
Trial: 39538139
Drug: Guideline-based antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-based antihypertensive therapy
Trial: 39538176
Drug: Sonidegib 200
RxNorm normalized name: sonidegib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonidegib 200 mg orally once daily
Trial: 39538331
Drug: Neoantigen DNA
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoantigen DNA vaccine administered via electroporation, three doses encoding an average of 11 neoantigens per patient (range 4-20).
Trial: 39539144
Drug: Triazavirin (TZV)
DrugBank: Triazavirin (DB15622)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazavirin (TZV) 250 mg capsules three-times daily for 7 days
Trial: 39539144
Drug: Oseltamivir 75
RxNorm normalized name: oseltamivir 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 75 mg capsules twice per day for 7 days
Trial: 39539664
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with anticoagulants and antiplatelet agents
Trial: 39540459
Drug: My Grief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: My Grief app (based on cognitive-behavioural therapy)
Trial: 39540661
Drug: Sunitinib (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (37.5 mg/day on days 1-14, 25 mg/day afterward) plus nivolumab (3 mg/kg every 2 weeks)
Trial: 39540734
Drug: Isavuconazonium sulfate
RxNorm normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Isavuconazonium sulfate 10 mg/kg daily (maximum 372 mg; equivalent to 5.4 mg/kg or 200 mg isavuconazole) for up to 84 days (IA) or 180 days (IM)
Trial: 39540734
Drug: Isavuconazonium sulfate
RxNorm normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Isavuconazonium sulfate 10 mg/kg daily
Trial: 39540734
Drug: Simulated doses
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated doses of 15 mg/kg
Trial: 39540799
Drug: Standard care:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care: TDF starting at gestational week 28 with HBV vaccinations and HBIG administered to the infant
Trial: 39540934
Drug: safinamide 100
RxNorm normalized name: safinamide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: safinamide 100 mg/day after 2 weeks of 50 mg/day
Trial: 39541202
Drug: Toripalimab plus
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab plus etoposide and platinum-based chemotherapy (EP)
Trial: 39541202
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus etoposide and platinum-based chemotherapy (EP)
Trial: 39541755
Drug: L test
RxNorm normalized name: CHOLESTEROL TEST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L test
Trial: 39542642
Drug: L-TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-TAP block
Trial: 39542995
Drug: Sovateltide (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sovateltide (0.3 µg/kg) administered intravenously in three doses at 3 ± 1 h intervals on Days 1, 3, and 6.
Trial: 39543001
Drug: 300-mg BUP-XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300-mg BUP-XR injection in the upper arm
Trial: 39543001
Drug: 300-mg BUP-XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300-mg BUP-XR injection in the thigh
Trial: 39543001
Drug: 300-mg BUP-XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300-mg BUP-XR injection in the buttocks
Trial: 39543001
Drug: 300-mg BUP-XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300-mg BUP-XR injection in the abdomen (reference)
Trial: 39543001
Drug: Safety evaluations
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety evaluations including treatment-emergent adverse events and assessments of injection site pain, tenderness, erythema, induration, and swelling
Trial: 39543340
Drug: NEIVATECH system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEIVATECH system (9 hours of therapy, 18 half-hour sessions over 1 month)
Trial: 39544014
Drug: Ergothioneine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergothioneine (25 mg per capsule, taken 3 times a week for one year)
Trial: 39544430
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of NabPaclitaxel-PIPAC and systemic NabPaclitaxel-Gemcitabine
Trial: 39545610
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus PD-1 inhibitor and radiotherapy
Trial: 39545967
Drug: Once-daily iTBS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily iTBS
Trial: 39545967
Drug: Twice-daily iTBS
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily iTBS
Trial: 39546040
Drug: Almond consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almond consumption (50 g daily)
Trial: 39546477
Drug: Immediate office-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate office-based vergence/accommodative therapy with movement (OBVAM)
Trial: 39547230
Drug: High-dose AAV8.TBG.hARSB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose AAV8.TBG.hARSB gene therapy (single intravenous infusion)
Trial: 39547249
Drug: FYTF-919 (Zhongfeng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FYTF-919 (Zhongfeng Xingnao) oral solution, 33 mL every 8 hours for 28 days (or 25 mL via nasogastric tube if swallowing impaired)
Trial: 39547249
Drug: Placebo, matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, matching appearance and administration as FYTF-919
Trial: 39547832
Drug: Bioresorbable vascular
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioresorbable vascular scaffold (BVS) implantation with prolonged dual antiplatelet therapy (DAPT) for 36 months
Trial: 39547981
Drug: Lipid-lowering drug
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering drug targets gene variants (specific SNPs not detailed)
Trial: 39548306
Drug: G-CSF only
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF only (G)
Trial: 39548306
Drug: Standard chemotherapy/G-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy/G-CSF (CG)
Trial: 39548607
Drug: Illioinguinal/iliohypogastric nerve
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Illioinguinal/iliohypogastric nerve block with 20 ml of 0.25% ropivacaine
Trial: 39548607
Drug: Wound infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wound infiltration with 10 ml of 0.25% ropivacaine
Trial: 39549554
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of spermidine, nicotinamide, PEA, and OEA supplements
Trial: 39549554
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose of spermidine, nicotinamide, PEA, and OEA supplements
Trial: 39549554
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of spermidine, nicotinamide, PEA, and OEA supplements
Trial: 39549554
Drug: All supplement
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All supplement doses combined
Trial: 39549719
Drug: Setmelanotide (subcutaneous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setmelanotide (subcutaneous, once daily for 52 weeks, starting at 0.5 mg with increments of 0.5 mg every 2 weeks)
Trial: 39549720
Drug: HIPEC (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIPEC (cisplatin 75 mg/m²)
Trial: 39550721
Drug: Finerenone (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finerenone (titrated to 20 mg or 40 mg)
Trial: 39551007
Drug: Adjunct dextromethorphan
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunct dextromethorphan (30 mg)
Trial: 39551007
Drug: Adjunct placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunct placebo
Trial: 39551057
Drug: Community-based screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based screening and treatment for Chlamydia trachomatis and Neisseria gonorrhoeae (males and females) and Trichomonas vaginalis (females only) offered over 12 months.
Trial: 39551057
Drug: Community-based screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based screening and treatment for Chlamydia trachomatis and Neisseria gonorrhoeae.
Trial: 39551057
Drug: Community-based screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based screening and treatment for Trichomonas vaginalis.
Trial: 39551057
Drug: Community-based screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based screening and treatment for Neisseria gonorrhoeae.
Trial: 39551062
Drug: MDA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDA with dihydroartemisinin-piperaquine and ivermectin (300 μg/kg per day)
Trial: 39551064
Drug: Durvalumab 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 1500 mg starting 2 weeks before radiotherapy then every 4 weeks starting week 2 of radiotherapy (seven cycles)
Trial: 39551064
Drug: Cetuximab 400
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab 400 mg/m2
Trial: 39551132
Drug: Apixaban, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban, 2.5 mg twice daily for three months
Trial: 39551147
Drug: HIV prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV prevention intervention as treatment per usual (active control)
Trial: 39551147
Drug: Weekly PrEP
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly PrEP adherence assessments
Trial: 39551356
Drug: Complementary dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary dietary fibers (total dietary fiber - complementary foods (g))
Trial: 39551469
Drug: Deulorlatinib 60
RxNorm normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Deulorlatinib 60 mg once per day (recommended phase 2 dose)
Trial: 39551600
Drug: MEDI5395 (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI5395 (recombinant attenuated Newcastle disease virus) administered intravenously as six doses over 15-18 days
Trial: 39551600
Drug: Durvalumab (anti-PD-L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (anti-PD-L1 immune checkpoint inhibitor)
Trial: 39551735
Drug: Three daily
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three daily assessments of depressive symptoms across one menstrual cycle
Trial: 39551791
Drug: HTNV DNA
RxNorm normalized name: HTNV DNA vaccine
DrugBank: Hantaan virus DNA vaccine (DB17808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTNV DNA vaccine (2 mg/vaccination)
Trial: 39551791
Drug: PUUV DNA
RxNorm normalized name: PUUV DNA vaccine
DrugBank: Puumala virus DNA vaccine (DB17809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUUV DNA vaccine (2 mg/vaccination)
Trial: 39551791
Drug: Combined HTNV/PUUV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined HTNV/PUUV DNA vaccine (2 mg/vaccination of 1:1 mixture)
Trial: 39551791
Drug: HTNV DNA
RxNorm normalized name: HTNV DNA vaccine
DrugBank: Hantaan virus DNA vaccine (DB17808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTNV DNA vaccine
Trial: 39551791
Drug: PUUV DNA
RxNorm normalized name: PUUV DNA vaccine
DrugBank: Puumala virus DNA vaccine (DB17809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUUV DNA vaccine
Trial: 39552638
Drug: 2LM niraparib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2LM niraparib monotherapy
Trial: 39554834
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus brief healthy diet and exercise education (MET+LIFE)
Trial: 39555642
Drug: Laughter yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laughter yoga (twice a week for 35-40 minutes, six sessions total)
Trial: 39555818
Drug: Oral infigratinib
RxNorm normalized name: infigratinib
DrugBank: Infigratinib (DB11886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral infigratinib at 0.25 mg/kg for 18 months (cohort 5)
Trial: 39555820
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drug therapy (sotalol or amiodarone)
Trial: 39555826
Drug: Tirzepatide (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide (up to 15 mg subcutaneously once per week)
Trial: 39556016
Drug: RP-A501 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RP-A501 infusion with transient immunomodulatory regimen (prednisone, tacrolimus or sirolimus, and rituximab)
Trial: 39556016
Drug: RP-A501 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RP-A501 infusion
Trial: 39556397
Drug: Baby Hand-Arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baby Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE), 50 hours over 2 weeks
Trial: 39556768
Drug: Muvalaplin 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muvalaplin 10 mg/d
Trial: 39556768
Drug: Muvalaplin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muvalaplin 60 mg/d
Trial: 39556768
Drug: Muvalaplin 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muvalaplin 240 mg/d
Trial: 39556772
Drug: Secretin infusion
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Secretin infusion (1 pmol/kg/min)